Full question: Will the "Biosecurity Modernization and Innovation Act of 2026" (S.3741) or a successor bill containing a mandate for DNA synthesis screening be signed into US law by 31st December 2027?

Background

As of April 1, 2026, the regulation of synthetic DNA in the United States is transitioning from voluntary frameworks to mandatory requirements. While the 2023 HHS Screening Framework Guidance established best practices, the May 5, 2025, Executive Order, "Improving the Safety and Security of Biological Research," mandated that federal agencies ensure synthetic nucleic acid procurement is conducted through providers adhering to an updated screening framework Improving the Safety and Security of Biological Research. Furthermore, the Executive Order directed the development of a strategy to govern non-federally funded research and mandated the submission of a legislative proposal to address gaps in authority to achieve comprehensive, scalable, and verifiable nucleic acid synthesis screening in non-federally funded settings Improving the Safety and Security of Biological Research.

The "Biosecurity Modernization and Innovation Act of 2026" (S.3741), introduced on January 29, 2026, by Senator Tom Cotton (R-AR) and co-sponsored by Senator Amy Klobuchar (D-MN), serves as the legislative vehicle for this administration-backed initiative to extend mandatory screening requirements to the entire industry S.3741 - Biosecurity Modernization and Innovation Act of 2026 ... Improving the Safety and Security of Biological Research. This forecasting question tracks whether the U.S. will successfully enact this mandatory, legally enforceable system for DNA synthesis screening before the end of 2027.

Resolution Criteria

This question will resolve as Yes if, between January 1, 2026, and 23:59 UTC on December 31, 2027, the Biosecurity Modernization and Innovation Act of 2026 (S.3741) or a successor bill is "signed into law" by the President of the United States or otherwise enacted via constitutional processes.

• DNA Synthesis Screening: Defined as the process of identifying whether a requested or synthesized nucleic acid sequence matches a "Sequence of Concern" (SOC) to prevent the misuse of synthetic biology for creating pathogens or toxins.

• Mandatory Requirement: The enacted legislation must contain a provision that makes screening and/or customer verification a legal requirement for "covered providers" (entities synthesizing/selling synthetic nucleic acids or benchtop synthesis equipment). The mandate must apply to all "covered providers" as defined in S.3741, regardless of revenue or organizational size, including both synthesis services and benchtop equipment manufacturers S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... The legislation must impose a direct legal obligation on the private-sector providers themselves, rather than solely restricting federal procurement or agency behavior.

• Penalties: The penalties for non-compliance must include punitive measures such as civil fines, statutory damages (e.g., as described in Section 4(f) of S.3741), or revocation of operating licenses, rather than just a loss of optional federal funding S.3741 - Biosecurity Modernization and Innovation Act of 2026 ....

• Successor Bill: A bill qualifies as a successor if it originates from the same legislative intent as S.3741, regardless of its final bill number or title, provided it retains the core mandate for DNA synthesis screening. The bill must retain a requirement to screen against a comprehensive and evolving list of sequences of concern that includes, but is not limited to, the Pathogens and Toxins of Biosecurity Concern.

• Signed into Law: This includes the President signing the bill, the bill becoming law without a signature after 10 days while Congress is in session, or Congress successfully overriding a presidential veto. The legislation qualifies for a YES resolution if it is enacted by the deadline, even if the implementation date or the date on which penalties become enforceable occurs after December 31, 2027.

• Resolution Source: The official status and text of the legislation as tracked on Congress.gov for bill S.3741 (119th Congress) or its successors. The "All Actions" and "Text" tabs will be used to verify enactment and the presence of the mandatory screening provision.

Forecast Rationale

There are 639 days left until the Dec. 31, 2027 resolution date. The status quo, if nothing changes, is NO: S.3741 is still only introduced and sitting in Senate Commerce with no hearings or markup yet S.3741 - Biosecurity Modernization and Innovation Act of 2026 ... All Info - S.3741 - 119th Congress (2025-2026): Biosecurity .... On a narrow scope of just this standalone bill, the odds are low; historically only about 2-3% of Senate bills become law, and only about 10-20% of referred bills even get a hearing or markup All Info - S.3741 - 119th Congress (2025-2026): Biosecurity .... On the broader scope that matters for resolution, a successor bill or an NDAA/omnibus rider makes passage materially more plausible, especially because similar biosecurity language has recently ridden the NDAA, which has passed for 64 straight years The BIOSECURE Act Becomes Law in the United States | Advisories. The main NO case is legislative inertia, crowding by higher-priority issues, and the risk that any eventual compromise adds exemptions or softens obligations enough to fail this question's strict all-covered-providers plus penalties criteria All Info - S.3741 - 119th Congress (2025-2026): Biosecurity ... S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... The YES case is unusually strong for a niche bill: bipartisan Cotton/Klobuchar sponsorship, explicit alignment with the 2025 executive order calling for a legislative proposal, likely presidential support if it reaches the desk, and a plausible must-pass vehicle path S.3741 - Biosecurity Modernization and Innovation Act of 2026 ... All Info - S.3741 - 119th Congress (2025-2026): Biosecurity ... The BIOSECURE Act Becomes Law in the United States | Advisories. In betting terms, I would be roughly indifferent between buying YES at 36 cents and NO at 64 cents; above that, I prefer NO because the committee-stage starting point still dominates.

Full analysis: decomposition, probabilistic components, and multi-method reconciliation

Generated by the Paper-to-Forecast pipeline — an automated system that transforms research papers into calibrated forecasting questions.